48-Hour Total Artificial Lung Bridge Enables Life-Saving Double Lung Transplant in Critical Lung Failure Case

A 48-hour bridge to a transplant rewrites an old rule in lung failure

For a critically ill 33-year-old man in spring 2023, standard organ support was no longer buying time. Surgeons removed both infected lungs and ran his circulation through a custom “total artificial lung” (TAL) for 48 hours-long enough to reverse multi‑organ collapse and perform a double‑lung transplant. “He was so sick, he had a cardiac arrest and he was actively dying,” said thoracic surgeon Ankit Bharat. “Within 48 hours, he was off all the medication to support his blood pressure, his kidney function was completely restored and his heart was working normally.” ([nature.com](https://www.nature.com/articles/d41586-026-00239-y?utm_source=openai))

What made this possible inside the operating room

The team engineered the TAL to do more than oxygenate blood. It also stabilized blood flow across the heart, solving a hemodynamic problem that typically follows total lung removal. Unlike conventional extracorporeal membrane oxygenation (ECMO), which usually supports failing lungs in situ, this device was designed to sustain a patient who had no lungs at all for a defined, short window. A transplant clinician who reviewed the approach put it plainly: “They were really very brave.” ([nature.com](https://www.nature.com/articles/d41586-026-00239-y?utm_source=openai))

This configuration overcame a historical limitation of extracorporeal support following bilateral pneumonectomy: without controlled flow across the heart, patients destabilize quickly. ([sciencealert.com](https://www.sciencealert.com/surgeons-kept-a-man-alive-with-no-lungs-for-48-hours-heres-how?utm_source=openai))

The patient journey at a glance

• Spring 2023: Severe influenza progressed to pneumonia, sepsis, and acute respiratory distress syndrome (ARDS); the bacterial infection proved resistant to multiple antibiotics. “He had developed an infection of his lungs that just could not be treated with any antibiotics because it was resistant to everything.” ([sciencealert.com](https://www.sciencealert.com/surgeons-kept-a-man-alive-with-no-lungs-for-48-hours-heres-how?utm_source=openai))
• Day 0: On arrival, cardiac arrest occurred; surgeons removed both lungs and initiated TAL support. “That infection caused his lungs to liquify and then continued to progress to the rest of his body.” ([sciencealert.com](https://www.sciencealert.com/surgeons-kept-a-man-alive-with-no-lungs-for-48-hours-heres-how?utm_source=openai))
• Hours 0-48: Shock reversed, kidney and heart function recovered on TAL support, creating a narrow but critical window in which the patient was stable enough to receive donor organs.
• Hour ~48: Double‑lung transplant performed once suitable organs became available.
• Long‑term: “We are now approaching almost three years since we did this, and the patient is doing really great.” ([nature.com](https://www.nature.com/articles/d41586-026-00239-y?utm_source=openai))

Where this fits in today’s transplant practice

The case challenges a common assumption about ARDS management windows and transplant candidacy. “Conventionally, lung transplant is reserved for patients who have chronic conditions like interstitial lung disease or cystic fibrosis,” Bharat said. “Currently, people think if you get severe ARDS, you keep supporting them and ultimately the lungs will get better.” He countered that, in selected patients with irreversible injury, immediate transplant can be lifesaving: “For severe lung damage caused by respiratory infections, even in acute settings, a lung transplant can be lifesaving.” ([sciencealert.com](https://www.sciencealert.com/surgeons-kept-a-man-alive-with-no-lungs-for-48-hours-heres-how?utm_source=openai))

That stance nudges transplant programs, critical‑care teams and ethics committees toward harder, earlier decisions: at what point is a damaged lung biologically non‑recoverable, and how aggressively should scarce donor organs be offered to acutely ill patients who would once have been seen as “too unstable” to list?

Allocation policy and how a donor lung finds a recipient

In the United States, lung offers are now prioritized using a single, points‑based composite allocation score (CAS), implemented March 9, 2023, under the national Organ Procurement and Transplantation Network. The framework weighs both urgency and post‑transplant benefit, which can influence how quickly highly unstable patients-like those requiring an artificial‑lung bridge-receive organ offers.

• Key attributes in CAS weighting:
  • Medical urgency
  • Expected post‑transplant outcome
  • Biologic match constraints (e.g., blood type, sensitization, size)
  • Pediatric priority (age under 18)
  • Prior living donation
  • Logistics and travel efficiency/distance
• Post‑implementation monitoring shows a shift toward more transplants for higher‑urgency candidates, with ongoing policy refinements (for example, improving access for blood type O candidates). These data will shape whether similar “lung‑free bridge” cases are seen as appropriate uses of the highest‑priority scores.

Regulatory guardrails for devices that act like lungs

• Component devices such as membrane oxygenators and nonroller blood pumps are regulated medical devices; oxygenators used in bypass have long been classified as a Class II oxygenator with special controls and defined performance expectations under U.S. Food and Drug Administration rules.
• When clinicians assemble novel configurations for a single patient in a life‑threatening emergency, U.S. pathways include emergency use and expanded access (individual or “compassionate” use), typically with rapid institutional oversight, documentation requirements and post‑hoc reporting to regulators. Those processes, while streamlined for crisis care, still influence how quickly a team can move from experimental concept to an approved bedside configuration.

System capacity: who can do this today?

• Only transplant centers with advanced cardiothoracic surgery, perfusion and critical‑care teams-and robust governance around high‑risk innovation-can safely attempt a lung‑free bridge.
• Round‑the‑clock perfusion staffing and rapid blood‑bank, imaging and operating‑room availability are prerequisites.
• Close coordination with organ‑procurement teams is essential to align stabilization windows with organ arrival under the CAS framework, which now explicitly factors transport distance and anticipated travel time into organ‑offer decisions.

Risks, limits, and what experts are watching

• Clotting, bleeding and infection remain inherent risks with extracorporeal circuits; the TAL’s balanced‑flow design aims to lower-but not eliminate-these hazards. ([sciencealert.com](https://www.sciencealert.com/surgeons-kept-a-man-alive-with-no-lungs-for-48-hours-heres-how?utm_source=openai))
• The approach is not a treatment for ARDS itself; rather, it is a time‑limited bridge when lungs are irrecoverable and infection control demands immediate removal.
• Peer commentary underscores both promise and caution: “They were really very brave.” ([nature.com](https://www.nature.com/articles/d41586-026-00239-y?utm_source=openai))
• For hospitals and regulators, wider adoption would likely demand formal trials, standardized device configurations and clearer criteria for which patients are offered a lung‑free bridge versus continued conventional support.

Why this matters beyond one operating room

If adopted more widely, a lung‑free bridge could change the calculus for a subset of patients whose lungs are biologically beyond repair yet who cannot safely wait for a transplant. Bharat’s assessment is stark: “In my practice, young patients die almost every week because no one realized that transplantation was an option.” ([sciencealert.com](https://www.sciencealert.com/surgeons-kept-a-man-alive-with-no-lungs-for-48-hours-heres-how?utm_source=openai)) For policymakers overseeing organ‑allocation rules, hospital boards setting risk thresholds and ethics committees weighing last‑chance interventions, this single case is a sign that the frontier of what “transplantable” looks like is still moving-and that governance will have to move with it.